Search - tctmd.com

Displaying 641 - 660 of 676

Sort: Relevancy | Date

News Daily News

MVARC Document Offers Template for Mitral Valve Therapeutics Research

Todd Neale

July 16, 2015

News Industry News

Thoratec Receives CE Mark Approval For HeartMate PHP™

July 13, 2015

News Industry News

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

July 09, 2015

News Daily News

Survival Benefit of CoreValve in High-Risk Patients Persists at 2 Years

July 07, 2015

News Industry News

Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril-valsartan)

July 07, 2015

News Daily News

RIBS IV: EES Surpass DCB for Treatment of In-Stent Restenosis

L.A. McKeown

July 01, 2015

News Daily News

RE-VERSE AD: El Antídoto de Dabigatran, Seguro y Eficaz en un Análisis Provisional

June 25, 2015

News Daily News

RE-VERSE AD: Dabigatran Antidote Appears Safe, Effective in Interim Analysis

June 25, 2015

News Daily News

RE-VERSE AD：中期分析表明达比加群中和剂似乎安全有效

June 25, 2015

News Industry News

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

June 09, 2015

News Industry News

Amgen Completes Enrollment In Large Cardiovascular Outcomes Trial Of Repatha™ (Evolocumab) In Patients With High Cholesterol And Clinically Evident Cardiovascular Disease

June 05, 2015

News Industry News

Global Cardiovascular Drug Delivery Market 2015 - Technologies, Markets and Companies

May 28, 2015

News Daily News

手术医生偶尔没有睡眠不会使 PCI 手术的安全性降低

January 28, 2015

News Daily News

Unless Chronic, Operator Sleep Deprivation Not Tied to Unsafe PCI

January 28, 2015

News Daily News

Las PCI No son Menos Seguras cuando los Operadores Pierden Sueño Ocasionalmente

January 28, 2015

News Daily News

‘Value’ of PCI Varies Widely Across VA Hospitals

Yael L. Maxwell

January 28, 2015

News Features

Advocacy Group Blasts Mobile Cardiovascular Screening Company for ‘Unethical’ Practices

Yael L. Maxwell

June 27, 2014

News Daily News

Apixaban Cost-Effective Compared with Warfarin or Aspirin

Caitlin E. Cox

February 26, 2014

News Conference News TCT 2013

Innovation in Intervention: Perspectives from Industry

October 30, 2013

News Daily News

FAME 2: FFR-Guided PCI ‘Economically Attractive’ vs. Medical Therapy Alone

Caitlin E. Cox

August 30, 2013

Advertisement

MVARC Document Offers Template for Mitral Valve Therapeutics Research

Thoratec Receives CE Mark Approval For HeartMate PHP™

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

Survival Benefit of CoreValve in High-Risk Patients Persists at 2 Years

Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril-valsartan)

RIBS IV: EES Surpass DCB for Treatment of In-Stent Restenosis

RE-VERSE AD: El Antídoto de Dabigatran, Seguro y Eficaz en un Análisis Provisional

RE-VERSE AD: Dabigatran Antidote Appears Safe, Effective in Interim Analysis

RE-VERSE AD：中期分析表明达比加群中和剂似乎安全有效

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

Amgen Completes Enrollment In Large Cardiovascular Outcomes Trial Of Repatha™ (Evolocumab) In Patients With High Cholesterol And Clinically Evident Cardiovascular Disease

Global Cardiovascular Drug Delivery Market 2015 - Technologies, Markets and Companies

手术医生偶尔没有睡眠不会使 PCI 手术的安全性降低

Unless Chronic, Operator Sleep Deprivation Not Tied to Unsafe PCI

Las PCI No son Menos Seguras cuando los Operadores Pierden Sueño Ocasionalmente

‘Value’ of PCI Varies Widely Across VA Hospitals

Advocacy Group Blasts Mobile Cardiovascular Screening Company for ‘Unethical’ Practices

Apixaban Cost-Effective Compared with Warfarin or Aspirin

Innovation in Intervention: Perspectives from Industry

FAME 2: FFR-Guided PCI ‘Economically Attractive’ vs. Medical Therapy Alone

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content